15 unknown, 14 recruiting, 5 active not recruiting, 3 completed. 23 Phase 3, 21 Phase 2, 6 Phase 1, 2 Phase 4, 1 Not applicable.
Follow Paclitaxel injection: new trials by email Literature Review of Paclitaxel injection trials Research Report on Paclitaxel injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer HB0025 Injection, Paclitaxel injection, Carboplatin injection - First-line pMMR Endometrial Cancer | Phase 3 | Recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 333 | 2026-10-20 | 2026-10-29 |
| A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection - Advanced Solid Tumour | Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 110 | 2026-02-26 | 2026-05-18 |
| Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer Carboplatin Injection, Paclitaxel Injection - Squamous Non-small Cell Lung Cancer | Phase 3 | Not yet recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 480 | 2026-01-15 | 2026-01-22 |
| A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer LBL-024 for Injection, Paclitaxel injection, Bevacizumab injection - Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 180 | 2025-12-02 | 2026-08-13 |
| A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer SHR-1316 Injection, Cisplatin Injection, Carboplatin Injection - Advanced Cervical Cancer | Phase 3 | Recruiting | Shanghai Shengdi Pharmaceutical Co., Ltd | 720 | 2025-10-17 | 2026-04-15 |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] LBL-024 for Injection, Docetaxel Injection, Bevacizumab Injection - Advanced Solid Tumour | Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 250 | 2025-06-11 | 2026-08-27 |
| A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer SHR-A1811, Carboplatin, Bevacizumab - Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 150 | 2025-03-18 | 2026-09-11 |
| A Study of SHR-A1811 in Subjects With Ovarian Cancer SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection - Ovarian Cancer | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 300 | 2025-03-13 | 2026-04-20 |
| A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection - Advanced Urothelial Carcinoma | Phase 3 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 402 | 2025-02-12 | 2025-07-17 |
| Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC Pembrolizumab 25 mg/ml, Paclitaxel injection - Triple-negative Breast Cancer | Phase 2 | Recruiting | UNICANCER | 354 | 2024-12-27 | 2026-07-24 |
| Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer WH002, paclitaxel injection - Breast Cancer | Phase 2 | Completed | Beijing Wehand-Bio Pharmaceutical Co., Ltd | 40 | 2024-09-10 | 2026-06-09 |
| A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors SHR-9839 for Injection, SHR-A1921 for Injection, SHR-A2009 for Injection - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 156 | 2024-07-02 | 2026-05-11 |
| A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) LVGN6051 Monoclonal Antibody Injection, toripalimab Injection, Paclitaxel injection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Lyvgen Biopharma Holdings Limited | 64 | 2024-06-21 | 2026-05-19 |
| A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer SHR-1316, Cisplatin Injection/Carboplatin Injection, External Beam Radiotherapy (EBRT)/Brachytherapy - Locally Advanced Cervical Cancer | Phase 2 | Unknown | Shanghai Shengdi Pharmaceutical Co., Ltd | 56 | 2024-03-20 | 2024-12-24 |
| DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy Disitamab Vedotin Injection, Cadonilimab Injection, Paclitaxel Injection - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | RemeGen Co., Ltd. | 90 | 2024-02-22 | 2024-04-03 |
| A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer TQB2868 injection, Paclitaxel injection, Cisplatin injection - Cervical Cancer | Phase 2 | Withdrawn | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-08-01 | 2023-11-22 | |
| Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer Tislelizumab, 5Fu, Paclitaxel injection - Gastric Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 39 | 2023-07-01 | 2023-06-22 |
| A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer MRG002, Docetaxel Injection, Paclitaxel Injection - Advanced or Metastatic Urothelium Cancer | Phase 3 | Recruiting | Shanghai Miracogen Inc. | 290 | 2023-04-06 | 2023-04-13 |
| Onvansertib + Paclitaxel In TNBC Onvansertib, Paclitaxel - Breast Cancer, Invasive Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Antonio Giordano, MD | 50 | 2022-09-30 | 2026-11-12 |
| QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer QL1706, Placebo, Paclitaxel injection - METASTATIC CERVICAL CANCER | Phase 3 | Unknown | Qilu Pharmaceutical Co., Ltd. | 498 | 2022-09-23 | 2022-11-30 |
Showing 20 of 44. Sign in to see all of them.
Breast Neoplasms (8) · Stomach Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (4) · Ovarian Neoplasms (4) · Uterine Cervical Neoplasms (3) · Head and Neck Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Esophageal Squamous Cell Carcinoma (1) · Inflammatory Breast Neoplasms (1) · Neoplasm Metastasis (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (4) · Nanjing Leads Biolabs Co.,Ltd (3) · RemeGen Co., Ltd. (3) · Biotech Pharmaceutical Co., Ltd. (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Qilu Pharmaceutical Co., Ltd. (2) · Shanghai Hengrui Pharmaceutical Co., Ltd. (2) · Shanghai Huaota Biopharmaceutical Co., Ltd. (2) · Shanghai Shengdi Pharmaceutical Co., Ltd (2) · UNICANCER (2) · Antonio Giordano, MD (1) · BeiGene (1) · Beijing Wehand-Bio Pharmaceutical Co., Ltd (1) · China Medical University, China (1) · Daehwa Pharmaceutical Co., Ltd. (1)
China (37) · France (2) · Bulgaria (1) · Germany (1) · Hungary (1) · Serbia (1) · South Korea (1) · Spain (1) · United States (1)
Aimin Zang (1) · Aiping Zhou, MD (1) · Airong Wang (1) · Antonio C Giordano, MD, PhD (1) · Baohui Han (1) · Barbara Pistilli, MD (1) · Binghe Xu (1) · Changlu Hu (1) · Elie Rassy, MD (1) · Fangjian Zhou, MD (1) · Fei Ma, MD (1) · Guohua Yu (1) · Haibo Wang (1)
PMID 17426445, PMID 24662947, PMID 33130217, PMID 33323401, PMID 34925553, PMID 37158938, PMID 39581197, PMID 39929333, PMID 41344593
2019 (1), 2023 (1)